Shionogi will pay BioVersys $6.3 million for developing BV500, BioVersys's drug candidate for non-tuberculous mycobacteria.

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60. Health ...

Kent County's latest measles case is part of a "troubling resurgence of vaccine-preventable diseases ... here and around the world.” ...

In its weekly update today, the US Centers for Disease Control and Prevention (CDC) reported 40 more measles cases today, ...

Following recent actions by the U.S. Department of Health and Human Services to restrict the approval and use of some ...